CLOs on the Move

ITC Nexus Dx

www.itcmed.com

 
ITC is a wholly-owned subsidiary of Thoratec and develops, manufactures and markets medical devices used in three distinct segments of the medical field.
  • Number of Employees: 25-100
  • Annual Revenue: $250-500 Million
  • www.itcmed.com
  • 8 Olsen Ave
    Edison, NJ USA 08820-2419
  • Phone: 732.548.5700

Executives

Name Title Contact Details

Similar Companies

Hannibal Regional Hospital

Hannibal Regional Hospital Foundation is a non-profit corporation (501,(c)3) and a part of the Hannibal Regional Healthcare System which exists to support Hannibal Regional Hospital by raising privately donated money.

Pana Community Hospital

Since 1914, Pana Community Hospital has been a place for quality health care. Our employees, medical staff, board of directors and management continue to strengthen and expand our hospital and its’ services. We are committed to your health care future, making our hospital a place you can count on. You can be sure our focus is on today and tomorrow…always striving to bring you quality health care close to home! Our Mission is to be a leading partner in assuring community-based quality Healthcare.

Zeltiq Aesthetics Inc

Zeltiq Aesthetics Inc is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.

US Script, Inc.

US Script, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Fresno, CA. To find more information about US Script, Inc., please visit www.usscript.com